Considerations and Challenges Surrounding CAR-T Therapy and Bispecifics

Jose Sandoval Sus, MD, discussed the “revolution” that CAR T-cell therapies have facilitated for patients with large B-cell lymphomas.

Advances in next-generation sequencing and gene expression are reshaping T-cell lymphoma classification and the use of targeted therapies.

The anti-CD19/4-1BB CAR T-cell therapy candidate elicited an ORR and CR rate of 100% each in patients with relapsed/refractory MCL.

Clinicians outline the significance of the MZL Workshop, where a gathering of international experts in the field discussed updates in the disease state.

The complete response letter for the agent is due to observations from an FDA general site inspection at Catalent Indiana, LLC.

Results from the phase 3 TRIANGLE trial showed prolonged failure-free survival and overall survival with ibrutinib and CIT vs CIT plus ASCT alone.